BridgeBio reports breakthrough results in Phase 3 achondroplasia trial
Achondroplasia is a genetic condition driven by FGFR3 that affects more than stature alone
Achondroplasia is a genetic condition driven by FGFR3 that affects more than stature alone
Semaglutide is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus
Operational leverage kicked in during the quarter, with adjusted EBITDA rising 21% year-on-year to Rs 147 crore
The company’s consolidated revenues rose 17.5% year-on-year to Rs. 2,265 crore
The FDA’s Center for Biologics Evaluation and Research (CBER) cited Moderna’s choice of a licensed standard-dose flu vaccine as the comparator in its Phase 3 trial, saying it “does not reflect the best-available standard of care.”
Under the deal, Uniphar will serve as LYMPHIR’s exclusive distribution partner across designated Western and Eastern European territories
ADQUEY’s approval opens the door to a new alternative for millions of Americans struggling with atopic dermatitis
Subscribe To Our Newsletter & Stay Updated